Precision Medicine World Conference

The Precision Medicine World Conference (PMWC), in its 13th installment, will take place in Silicon Valley on January 22-24, 2018. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

  • More than 70 sessions with 250+ thought-provoking, insightful talks that cover all facets of precision medicine
  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Advancements in liquid biopsy applications
    • AI and machine learning opportunities and applications
    • Big data and emerging technology applications that enable precision medicine
    • Biomarker and companion diagnostics
    • Cancer and rare disease diagnostics
    • Clinical NGS applications
    • Clinical trial developments
    • Clinical-decision support
    • CRISPR technologies
    • Digital, mHealth, and Telehealth
    • Drug discovery challenges and opportunities
    • Economics and socio-political aspects of PM
    • Immunotherapy applications
    • Infectious disease ID and monitoring
    • Large scale human genetics application in genomic medicine and drug discovery
    • Liquid biopsy applications
    • Metabolomics in precision medicine
    • Overcoming data sharing
    • Precision medicine initiatives
    • The All of Us Research Program
    • The human microbiome
    • The importance of patient engagement
    • Updates on data and regulatory policies
    • Valued-based healthcare
    • Wellness & Aging
    • Up-and coming company showcases

 

http://www.pmwcintl.com/2018sv-info/#agenda 

This website uses cookies for analytics purposes only without any commercial intent. Find out more here.

Accept cookies